coiled-coil and HOOK domain protein 88BGenealiases: BRLZ · CCDC88 · HKRP3 · gipie
Q-omics provides the consensus-scored CCDC88B profile across patient tissues and cancer cell-line models. CCDC88B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC88B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CCDC88B protein abundance shows 24,310 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CCDC88B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC88B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC88B survival associations across molecular data types. CCDC88B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC88B RNA expression–survival associations across cancer types. High CCDC88B expression shows unfavorable associations in KIRC, ACC, LGG and UVM, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC88B RNA expression.
This table summarizes CCDC88B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC88B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC88B shows higher tumor expression in KIRC, KIRP, STAD, THCA, LIHC and HNSC. The KIRC box plot shows higher CCDC88B RNA expression in tumor versus normal tissue (log2 FC = +1.753, t-test p < 0.001).
This table shows molecular features associated with CCDC88B in patient tissues and cancer cell lines. In patient samples, CCDC88B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC88B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
